Innate Pharma SA: Form 20-F for the period ended Dec 31, 2019
Filed with the SEC on Apr 24, 2020 and accepted by EDGAR at Apr 24, 2020, 10:43 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2019-01-01 to 2019-12-31 | EUR 85.8m | ifrs-full:Revenue |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −EUR 27.1m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2019-01-01 to 2019-12-31 | −EUR 20.8m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −EUR 0.31 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | −EUR 0.31 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | EUR 34.9m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | EUR 1.3m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2019-12-31 | EUR 202.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2019-12-31 | EUR 237.6m | ifrs-full:CurrentAssets |
| Total assets | At period end2019-12-31 | EUR 401.4m | ifrs-full:Assets |
| Current liabilities | At period end2019-12-31 | EUR 121.8m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2019-12-31 | EUR 217.4m | ifrs-full:Equity |
| Shares outstanding | At period end2019-12-31 | 78,580,464 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001171843-20-002847. Last ingested by Listed: Nov 5, 2026, 11:30 ET. Listed shows no prices and gives no investment advice.